Kornimate/medical-research-clean huggingface dataset:
foot and abdominal massage applied to after colonoscopy

Conditions: Abdominal Pain; Distention; Satisfaction, Patient

Summary: the aim of this study was to determine the effect of foot and abdominal massage applied to after colonoscopy on abdominal distention, pain and patient satisfaction.this was a randomized controlled experimental study conducted at the colonoscopy unit in medica faculty hospital . participants assigned to the intervention group-1 received foot massages after colonoscopy, participants assigned to the intervention group-2 received abdominal massages after colonoscopy and participants assigned to the intervention group-3 received foot and abdominal massages after colonoscopy. participants assigned to the control group received only "routine care" after colonoscopy. the abdominal pain, distension and satisfaction levels of the patients evaluated using the numerical rating scale

the aim of this study was to determine the effect of foot and abdominal massage applied to after colonoscopy on abdominal distention, pain and patient satisfaction.this was a randomized controlled experimental study conducted at the colonoscopy unit in medica faculty hospital . participants meeting inclusion criteria were assigned to intervention and control groups using a random. participants assigned to the intervention group-1 received foot massages after colonoscopy, participants assigned to the intervention group-2 received abdominal massages after colonoscopy and participants assigned to the intervention group-3 received foot and abdominal massages after colonoscopy. participants assigned to the control group received only "routine care" after colonoscopy. the abdominal pain, distension and satisfaction levels of the patients evaluated using the numerical rating scale

Eligibility criteria:
inclusion criteria: * being of 18 years of age and above * applying for colonoscopy for diagnosis and treatment, * being conscious and oriented to place, person and time, * having pain after the procedure, * no communication barriers, * able to communicate in turkish, * individuals who gave written consent to participate in the research were included in the study. exclusion criteria: * having any psychiatric disease, * those who have previously had bowel resection or another bowel surgery, * those with colostomy and ileostomy, * those with percutaneous endoscopic gastrostomy, * those with inflammatory bowel disease, * having a history of malignant intestinal obstruction in their health history, * diagnosed with colon cancer, * those with umbilical/abdominal hernia, * having an open wound in the abdominal and/or foot area, * those with active lower gastrointestinal system bleeding, * those with celiac disease, * patients with fmf disease were excluded from the study.
impact of sunscreen dispensers in parks visited by teenagers

Conditions: Skin Neoplasm; Adolescent Behavior; Sunscreening Agents

Summary: this study will evaluate the use of publicly available free sunscreen dispensers at maine beaches and boston and cambridge parks. aim 1: determine the impact of dfs+ (dispensers, flyers, enhanced signage, + a social media component delivered by teen ambassadors) sun protection education on the use of free sunscreen dispensers by adolescents ages 12-20 compared with dfs (dispensers, flyers, standard signage). aim 2: outcomes evaluation to assess the effects of the sunscreen dispensers and the sun-safety educational intervention on sun protection knowledge, attitudes, beliefs, and behaviors within the community. aim 3: cost evaluation and cost-effectiveness analysis

the investigators will build on the pioneering work of impact melanoma which has provided free sunscreen dispensers to a general population. this study will build on impact melanoma's ability to install, maintain, and now for the first time, target and publicize the use of dispensers for a teen population. the investigators will test scalable methods for improving the use of free sunscreen dispensers by testing dfs interventions compared with the addition of social media led by teen ambassadors. the investigators will evaluate the impact of the intervention in both parks and beaches in boston, ma, cambridge, ma and maine.

Eligibility criteria:
inclusion criteria: * being a boston, ma, cambridge, ma or maine youth ages 12-20 * able to complete a survey in english exclusion criteria: * not a boston, ma, cambridge, ma or maine youth ages 12-20 * not able to complete a survey in english

Keywords: skin neoplasm adolescent behavior sunscreening agents
safety study of mini-dystrophin gene to treat duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy

Summary: the purpose of this study is to determine the safety of a miniature dystrophin gene in the treatment of progressive muscle weakness due to duchenne muscular dystrophy (dmd).

this phase i randomized double blind dose escalation study investigates the safety and efficacy of the mini-dystrophin gene transferred to the biceps muscle for duchenne muscular dystrophy patients, ages 5 to 12 years of age, using a recombinant adeno-associated virus. eligible participants must have a known dystrophin gene mutation and may be concurrently treated with corticoid steroids. the mini-dystrophin gene or a placebo agent (normal saline or empty viral capsids) are injected directly into both biceps muscles while under conscious sedation. following the gene transfer, patients are admitted to the hospital for 48 hours of observation followed by weekly outpatient visits at the columbus children's hospital neuromuscular clinic. a bilateral muscle biopsy is preformed following 6 weeks with long term follow up will consisting of bi-annual visits for the next 2 years.

Eligibility criteria:
inclusion criteria: * known null mutation of the dystrophin gene * male age of 5 years or older * if taking corticosteroids, must have dose unchanged for the past 3 months * serum creatine kinase elevation greater than 10x normal value (established by children's hospital) * progressive, symmetrical proximal muscle weakness of arms and legs exclusion criteria: * unable to cooperate for muscle strength testing * joint contractures that prohibit muscle strength testing * concomitant illness * individuals predisposed to excessive vagal responses (bradyarrhythmia or hypotension) * controlled substance abuse

Keywords: duchenne muscle muscular dystrophy gene therapy dystrophin adeno-associated virus aav
comparing cade software for enhanced polyp detection

Conditions: Colonic Polyp; Colon Lesion

Summary: purpose \& research questions the purpose of this study is to evaluate whether artificial intelligence (ai) improves the detection of polyps and whether the system can classify the type and severity of detected changes. the investigators will also assess if there are any differences between the various ai systems and whether the polyps that may be missed are benign or malignant.

materials: selection, representativeness, and grouping the study is a randomized controlled clinical trial conducted at västra götaland region. patients are randomized to receive either ai or conventional endoscopy, and each endoscopy unit has access to at least one ai device. informed consent is obtained from patients before the examination. before the examination, patients are asked if they want to participate in the study. if the patient wishes to participate, informed consent is obtained. the endoscopist then draws a slip from an envelope, determining whether conventional colonoscopy or ai will be used. during conventional colonoscopy, the patient is examined according to routine practice. after the examination, a questionnaire is filled out, recording various findings from the examination. during ai examinations, the ai system is activated only during instrument withdrawal. the system identifies polyps and alerts the endoscopist. additionally, two of the ai systems (gi-genius, cadeye) have the ability to characterize the detected polyps and provide an interpretation of whether the changes are benign or malignant. after the examination, a similar questionnaire is completed as in conventional colonoscopy. method: data collection basic data will be recorded, including the reason for the examination, other illnesses, medications, demographic data such as gender, age, family history of cancer, and the time of the examination (morning or afternoon). during the examination, the following will be recorded: the number of polyps, macroscopic classification of polyps, ai system's characterization of the polyps, bowel cleansing quality, laxative method, medication during the examination, complications occurring during or after the examination. withdrawal time is recorded, as well as the number of false-positive polyps and supplementation with histological data of polyps after review by the pathologist. three different ai systems will be used at the various hospital sites, namely endoaid (olympus), cadeye (fujinon), and gi-genius (medtronic). all units will randomize each examination to either ai or non-ai.

Eligibility criteria:
inclusion criteria: * age \> 50 years * elective colonoscopy exclusion criteria: * patient declines to participate in the study. * age \< 50 years * emergency examinations * contraindications for biopsy/polypectomy * unprepared bowel
effect of prasugrel on platelets after one week in patients already taking clopidogrel after a cardiac event

Conditions: Coronary Arteriosclerosis; Acute Coronary Syndrome

Summary: this study will compare the effect of a prasugrel 10-mg maintenance dose with a clopidogrel 75-mg maintenance dose on platelet activity, approximately 1 week after the first dose of study drug, in subjects who have been taking clopidogrel 75 mg daily following a percutaneous coronary intervention (pci) with placement of a stent, performed to treat acute coronary syndrome (acs).


Eligibility criteria:
inclusion criteria: * present with a recent history of an acs event based on the disease diagnostic criteria between 30 and 330 days prior to enrollment, and who state that they are supposed to be taking daily aspirin and maintenance dose 75-mg clopidogrel. * are of a legal age (and at least 18 years of age but less than 75 years of age) and competent mental condition to provide written informed consent before entering the study. exclusion criteria: * left main coronary artery stent or left anterior descending (lad) bifurcation stent. * have any form of coronary revascularization (percutaneous coronary intervention \[pci\] or coronary artery bypass grafting \[cabg\]) planned to occur during the study (from signing consent through the final visit). * have undergone cabg or pci within 30 days of entry into the study. * receiving or will receive oral anticoagulation or other antiplatelet therapy (other than aspirin and clopidogrel) that cannot be safely discontinued for the duration of the study. * receiving daily treatment with nonsteroidal anti-inflammatory drugs (nsaids) that cannot be discontinued or are anticipated to require daily treatment with nsaids during the study. * have any of the following: history of ischemic or hemorrhagic stroke intracranial neoplasm, arteriovenous malformation, or aneurysm history of transient ischemic attack (tia), have a body weight less than 60 kilograms (kg).
study of the implantable cardioverter defibrillator (icd) intracardiac electrograms

Conditions: Congestive Heart Failure; Sudden Cardiac Death; Arrhythmia; Cardiomyopathies

Summary: the purpose of this study is to determine whether waveforms of the intracardiac electrograms, acquired through an icd, can be used: * to predict malignant ventricular arrhythmias, requiring appropriate icd therapies, and * to predict progression of heart failure in patients with icd.


Eligibility criteria:
inclusion criteria: * history of acute mi at least 4 weeks old * non-ischemic lv dysfunction for at least 9 months * who have an ef \< or = to 35% * who was resuscitated from sudden cardiac arrest (ventricular tachyarrhythmia) * undergone implantation of an fda-approved icd for primary or secondary prevention of scd exclusion criteria: * inability or unwillingness to provide valid informed consent * pregnancy * any condition other than cardiac disease that was associated with a high likelihood of death during 1 year after enrollment

Keywords: arrhythmia cardiac arrest cardiomyopathy heart failure
impact of photopheresis in the prevention of acute rejection in highly sensitized de novo kidney transplant recipients

Conditions: Kidney Transplant Rejection

Summary: the aim of the present study is to evaluate the superiority of photopheresis in combination with the standard immunosuppression vs standard immunosuppression alone for the prevention of acute rejection in highly sensitized kidney transplant recipients (cpra ≥90%). unicentric, randomized, open study.


Eligibility criteria:
inclusion criteria: * sensitized (cpra ≥90%) candidates for a deceased-donor kidney transplantation * recipients between 18 and 75 years old * patients are able to understand and sign informed consent (annex 1). exclusion criteria: * participation in another interventional clinical trial. * use of rituximab or eculizumab at the time of transplant or in the first 24 hours post-transplant. * persons with any dependency on the researcher or employee by the responsible institution or researcher. as well as people detained by legal order.

Keywords: kidney transplant rejection photopheresis antibody-mediated rejection chronic active antibody-mediated rejection
an observational study to learn more about the use of vericiguat in korean people with chronic heart failure with reduced ejection fraction (hfref) in real-world setting

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Summary: this is an observational study in which only data are collected from participants receiving their usual treatment. the study is done in people with chronic heart failure with reduced ejection fraction (hfref). hfref is a long-term condition in which the heart does not pump blood as well as it should. blood and fluid may collect in the lungs, blood vessels, and tissues causing shortness of breath or tiredness. over time, heart failure can lead to other serious medical conditions that may result in hospital stays and death. the study treatment vericiguat works by increasing the activity of an enzyme called soluble guanylate cyclase (sgc). sgc helps to regulate the heart and blood circulation. vericiguat has already been studied in previous clinical studies and is available for doctors to prescribe to people with heart failure. this study will collect important data from real-world setting in korea. the participants of this study are people with hfref who will receive vericiguat as prescribed by their doctors according to the approved product information the main purpose of this study is to learn more about how safe vericiguat is in the participants. to do this, researchers will collect data on all medical problems (also called adverse events) that the participants have during the study. doctors keep track of all adverse events, even if they do not think they might be related to the study treatment. further, researchers will collect data on how well vericiguat works and treatment patterns in the participants. for this, the following information will be collected: * occurrence of death due to heart and circulatory events * hospital stays due to heart conditions (failure) * dose levels of vericiguat and duration of treatment the data for this study will come from medical records and visits that take place in routine practice. participants will be treated with vericiguat and observed up to 12 months or until death or they leave the study, whatever comes first.


Eligibility criteria:
inclusion criteria: * adult aged 19 years or older * chronic hf (nyha functional class ii, iii, or iv) reduced left ventricular ejection fraction (\< 45%) within 12 months before enrollment * worsening of heart failure (hospitalized within 6 months before enrollment or intravenous diuretic therapy without hospitalization within 3 months) * participants who have been prescribed verquvo (vericiguat) as per locally approved label and didn't receive verquvo (vericiguat) therapy previously. * written informed consent from subject or legal representative; assent from subject when appropriate exclusion criteria: * contraindication according to the local authorized label (including known hypersensitivity to the drug substance or any of its components, pregnancy) * participants participating in an investigational program with interventions outside of routine clinical practice
conformal partial breast irradiation with cyberknife after resection for early stage breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to determine if it is feasible, safe, and effective to use cyberknife radiotherapy to deliver partial breast radiotherapy after lumpectomy.patients meeting eligibility criteria will be invited to participate. adjuvant radiotherapy will be delivered using cyberknife radiotherapy using twice daily sessions for five days for a total of ten sessions. short-term and long-term toxicity will be assessed as well as tumor control and site of failure (if any).

this study will determine the feasibility and toxicity of a short course of accelerated radiotherapy as adjuvant treatment for early stage breast cancer. successful completion of this project may provide a rationale to offer this treatment for select patients with the benefit of potentially less tissue damage and a shorter overall course of therapy. these improvements may ultimately allow more patients the opportunity of breast conserving therapy to treat their cancer

Eligibility criteria:
inclusion criteria: 1. diagnosis of breast malignancy, stage t1 2. surgical treatment with lumpectomy 3. age 60 or older 4. resection margins negative by at least 2mm 5. any grade 6. er positive 7. unicentric 8. invasive ductal 9. pathologic free of nodal metastases (n0, i- or i+) 10. post-lumpectomy cavity to whole breast ratio must be less than or equal to 30% exclusion criteria 1. prior radiotherapy to the breast 2. neoadjuvant chemotherapy 3. multicentric disease 4. pure dcis histology 5. presence of extensive intraductal component 6. node positive disease (n1 or greater)

Keywords: stereotactic radiotherapy cyberknife following lumpectomy breast cancer
different dosage of domestic and imported clopidogrel on the platelet inhibition ratio in patients undergoing pci

Conditions: Coronary Heart Disease

Summary: this is a single-center, randomized, single-blind, investigator-initiated, pharmacological study with a parallel design. patients with non-acs undergoing primary percutaneous coronary intervention will be randomized after informed consent, in a 1:1:1:1 ratio to the following treatment groups: group α: domestic clopidogrel 300mg as a loading dose before pci, followed by 75mg per day. group b: domestic clopidogrel 600mg as a loading dose before pci, followed by 75mg per day. group b: imported clopidogrel 300mg as a loading dose before pci, followed by 75mg per day. group d: imported clopidogrel 600mg as a loading dose before pci, followed by 75mg per day. platelet inhibition ratio assessment by thrombelastogram will be performed，2 hours after the loading dose(day 0)， 6 hours after thrombelastogram (day 0), 30 day after thrombelastogram. documentation of major adverse cardiac events (death, myocardial infarction, stroke, revascularization procedure with pci or cabg) and serious adverse events (bleeding, other adverse events)will be performed until day 30.


Eligibility criteria:
inclusion criteria: 1. the patient is scheduled to undergo non-urgent pci 2. the patient is between 18 and 75 years of age (inclusive) and willing to comply with the protocol 3. the patient or legally acceptable representative is able to read and give written informed consent and has signed an informed consent form approved by the investigator's irb/iec exclusion criteria: 1. estimated or measured weight \< 55 kg 2. acute non-st-segment elevation myocardial infarction (nstemi) or st-segment elevation myocardial infarction (stemi) within 7 days prior to pci 3. uncontrolled hypertension at the time of initial study drug administration defined as measured systolic blood pressure \> 190 mm hg or diastolic blood pressure \> 108 mm hg 4. patient has received a clopidogrel loading dose (≥300 mg) within 30 days prior to randomization; patients on maintenance clopidogrel may be enrolled 5. administration of thrombolytic agents, fondaparinux, or oral anticoagulants (e.g., warfarin) within the 7 days prior to pci 6. estimated creatinine clearance (e.g. cockcroft-gault) \< 45 ml/min 7. anemia with hemoglobin level \< 10 g/dl 8. thrombocytopenia (platelet count \< 100,000/mm3) 9. alt and/or ast \> 2.5 x the uln or other indication of clinically significant hepatic dysfunction 10. facial or head trauma within the last 30 days 11. intraocular hemorrhage within the last 30 days 12. gastrointestinal bleeding within the last 30 days 13. active bleeding, or history of a bleeding disorder or known intracranial vascular malformation 14. known allergy or contraindication to aspirin, heparin, clopidogrel, or to any contrast media 15. participation in any investigational drug study within 30 days prior to enrollment.

Keywords: clopidogrel; platelet inhibition ratio
discovering factors in narcolepsy patients' clinical research experiences

Conditions: Narcolepsy

Summary: an observational trial can provide a platform for patients to share experiences and perspectives on living with narcolepsy, which can inform the development of new treatments and support programs. overall, an observational clinical trial is an important tool for advancing the understanding of narcolepsy and improving outcomes for patients.


Eligibility criteria:
inclusion criteria: * patient is at least 18 years of age * patient is able and willing to comply with the treatment/follow-up schedule and requirements * patient must provide written informed consent exclusion criteria: * women who are pregnant, intend to become pregnant, or are lactating * inability to perform regular electronic reporting * participants who are vulnerable to any intervention

Keywords: narcolepsy